AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 32 min read$CORT

Mokari Atabak sold $9.2M of CORT

Mokari Atabak (Chief Financial Officer) sold 80,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $114.71 ($105.54–$120.67, $9.18M total) across 13 trades on 2026-07-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mokari Atabak
Published Aug 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:15 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosure updates the insider trading record and may influence short-term sentiment, but it does not provide new company fundamentals.

02

Market read

A CFO open-market sale of roughly $9.18M in CORT shares under a 10b5-1 plan is disclosed, with likely limited trading impact absent other catalysts.

03

What to watch

The filing does not disclose whether other insiders or the company announced offsetting catalysts (buybacks, guidance, trial updates), so traders should not infer fundamental deterioration from this alone.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-03, transaction dated 2026-07-30

Background

The article is an SEC Form 4 insider transaction report for Corcept Therapeutics, filed by the CFO.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics CFO Mokari Atabak sold about $9.18M of CORT shares via an open-market sale under a 10b5-1 plan on 2026-07-30.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst from the filing alone.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no accompanying company-specific news (earnings, guidance, deals, or regulatory actions).

Market effects

Sector

Minimal. Insider sales under 10b5-1 typically do not reset sector fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, the transaction may reflect liquidity planning rather than bearish expectations, so any price reaction may be overdone.

Key entities

  • issuer
    Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Mokari Atabak

    Chief Financial Officer who sold shares.

Read at source← All news

Related articles

AUG 6
$CORTHighAI 9/10

Raised Guidance Lifts Corcept to 52-Week High

Corcept Therapeutics (CORT) reported fiscal 2026 Q2 results with record revenue of $256.1 million, up 32% year over year, and net income of $43 million, up 22.9%. The company had $545 million in cash and investments and raised 2026 revenue guidance to as much as $1.2 billion, sending shares to a 52-week high.

yahoo.com3 min
JUL 31
$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min
JUL 31
$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

rttnews.com6 min
JUL 31
$CORTMed

Corcept Therapeutics Q2 Earnings Call Highlights

Vieira said the company continues to add patients weekly and is seeking to expand use among additional physicians and practices. He said Corcept expects LIFYORLI's U.S. annual revenue in platinum-resistant ovarian cancer alone to exceed $1 billion as adoption grows. In its pivotal ROSELLA study, LIFYORLI combined with nab-paclitaxel chemotherapy met both primary endpoints, according to Chief Executive Officer Joe Belanoff.

yahoo.com6 min
JUL 31
$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

rttnews.com6 min
JUL 30
$METAMed

Futures Rise As Oil Drops, Bond Selling Slows, Meta Tumbles And Microsoft Soars

US stock index futures rose in premarket after a prior selloff tied to Fed-related concerns. Microsoft shares jumped about 9% after cloud growth accelerated, while Meta fell about 8% after revenue guidance disappointed and free cash flow was weak. Bond selling slowed and 30-year yields hit a two-decade high near 5.22%. Several other earnings moves were reported, including MO, CVNA, CMG, and QCOM.

zerohedge.com7 min